Fair-Value Report — Softcare Limited (2698.HK)

Insider Signal

Verified Snapshot — All prices as of 3 Jun 2026

Financials reported in USD. HKD conversion at 7.80. FY2025 = year ended 31 Dec 2025; annual results announced 20 Mar 2026. All figures from stockanalysis.com (cross-checked against HKEX news filings). Revenue growth: USD 319.9M (FY22) → 411.4M (FY23) → 454.4M (FY24) → 567.4M (FY25) — 3-year CAGR 21%.

Business Overview

Softcare Limited is a UAE-headquartered, HKEX-listed manufacturer and distributor of disposable hygiene products — baby diapers, training pants, sanitary napkins, and wet wipes — sold under brands including Softcare, Veesper, Maya, Cuettie, and Clincleer. Founded as a trading arm of the Sunda Group in 2009 (Sunda itself founded 2000 by Yang Yanjuan and Shen Yanchang), the company evolved into a localised producer with eight manufacturing facilities on the African continent.

Core moat: Grassroots distribution. Instead of working through major national distributors, Softcare built direct relationships with tens of thousands of smaller agents and local retailers across African communities. This network — built over 15+ years with initial losses absorbed by management — is expensive to replicate and is the primary source of the company's 20% market share by volume in core hygiene segments.

Structural opportunity: Sub-Saharan Africa accounts for 36% of global births yet diaper penetration is only 20% vs 70–86% in developed markets. Sanitary pad penetration is approximately 30%. Over 30 million newborns annually provide a baseline demographic tailwind. Frost & Sullivan projected the African baby diaper market to reach USD 2.9B by 2029 (6.8% CAGR) and the overall hygiene market to grow from USD 3.8B at 6.8% annually.

Risks embedded in the model: African currency devaluations (revenues earned in local currencies vs USD reporting); political/regulatory opacity; competition from multinationals (P&G, Kimberly-Clark) entering Africa; elevated capex cycle compressing near-term FCF.

Valuation

Method: Three-Scenario DCF (primary) + Forward P/E Peer Multiple (anchor)

Softcare is a profitable, growing consumer operating company. No FCF-only DCF is used — FCF margin is temporarily depressed by expansion capex (USD 52M in FY2025 vs USD 5.8M in FY2023); operating income is the cleaner earnings measure. All DCF inputs in USD; share prices converted to HKD at 7.80.

WACC (CAPM, computed via wacc.py)

Three-Scenario DCF — Output (scripts/dcf.py, 10-year explicit period)

DCF uses WACC 12.63% across all scenarios; NOPAT-based with SBC 0.5% of revenue; net cash USD 424.2M added back; 619.52M diluted shares. Terminal value ranges 42–68% of EV, within normal bounds for a growing consumer company.

Reverse DCF — What Does HKD 27.30 Imply?

At HKD 27.30 (USD 3.50), holding base-case margins and WACC constant, the market is pricing in a flat revenue CAGR of approximately 15% for 10 years — meaningfully below the current 25% run-rate but achievable. Alternatively, the market prices in a flat operating margin of 27.5% (300bp above current 25.2%), implying the market needs either sustained growth near consensus or margin improvement to justify current price. On a standalone DCF basis, the stock is approximately fairly priced relative to the base case; the thesis for upside rests on growth sustaining above the implied 15% CAGR and/or FCF margin expansion as the capex cycle peaks.

Sector Multiple Anchor — Forward P/E

FY2026E EPS estimated at HKD 2.10–2.15, assuming 20% revenue growth and stable 21% net margins. At 18x forward P/E (fair for a 20–25% growth EM consumer company), the implied price is HKD 38–39. Analyst consensus of HKD 41.44 implies approximately 19–20x forward P/E, consistent with this range.

Peer Relative Valuation

Peer read: Softcare trades at a 20% discount to the peer median P/E (15.25x vs 19x), despite growing approximately 5× faster than the median peer and delivering nearly double the net margins. PEG of 0.61 vs peer median 5.2 is a dramatic discount on a growth-adjusted basis. This supports the analyst consensus view of HKD 38–41 as a re-rating target. However, the peer set is imperfect: Hengan and Kimberly-Clark are mature DM/China businesses; Unicharm is the best comp but trades on Japan premium. The 20% discount to peers is partially justified by higher EM risk and short post-IPO track record, but the magnitude appears excessive given fundamentals.

Conclusion & Rating

The honest position: on a standalone three-scenario DCF, Softcare is approximately fairly priced against base-case assumptions (implied growth of 15% flat, close to consensus fade). The bull case (+59%) requires growth sustaining near 20–25% — plausible given Africa's structural demand gap but not certain. The bear case (–48%) would require significant margin deterioration (to 16% by year 10) from current 25% levels, driven by currency headwinds or competitive entry — a real risk.

The Speculative Buy call is grounded in three converging positives:

1. Founder conviction: Yang Yanjuan committed HKD 80.8M of personal capital on June 2, 2026 — at near-IPO price, 24 days after her lock-up expired and she was free to sell. This is not a token buy; it is the largest individual insider purchase since listing.
2. Peer discount: A 20% P/E discount to slow-growth global peers while growing at 25% is structurally anomalous. FCF margin (11%) is depressed by a capex cycle; as new African factories ramp, FCF should recover toward 15–18% and re-rate the stock toward peers.
3. Structural runway: Africa's 20% diaper penetration vs 70–86% in developed markets represents a multi-decade growth trajectory. Softcare's proprietary grassroots distribution moat is difficult and expensive to replicate.

The call is speculative, not high-conviction, because: (1) the DCF base case is already at current price, meaning the margin of safety is thin; (2) EM currency devaluations could erode USD-reported profits even if volumes grow; (3) the company has only 7 months of post-IPO public history, limiting the audited track record; (4) a second 6-month lock-up expires November 2026, creating a potential overhang.

Key Risks

• African currency devaluations: Revenues are earned in local currencies (CFA franc, Ghanaian cedi, Kenyan shilling, etc.) but reported in USD. Repeated devaluations could significantly reduce reported USD revenue and profits even with underlying volume growth. This is the single highest-impact risk.
• Political and regulatory risk: Operating across 20+ African nations introduces country-specific tariff, regulatory, and political disruption risk. A single large market becoming unfavourable could materially impact earnings.
• Capex cycle & FCF conversion: Reported FCF (USD 63.3M) represents only 52% of net income, compared to 75–100% typical for mature consumer goods. If expansion capex remains elevated for 3+ years, the stock may re-rate downward on FCF-based frameworks.
• Multinational competition: Procter & Gamble and Kimberly-Clark have been increasing Africa investment. Their brand recognition, R&D, and global procurement advantages could erode Softcare's margins and market share over time.
• Post-IPO lock-up overhang: The second 6-month lock-up expires November 2026. Selling by pre-IPO shareholders could depress the stock near that date.
• Nominee holding structure: Yang Yanjuan holds via Century Investment Limited (BVI), so the ultimate beneficial motivation for the purchase is not directly verifiable in the DI form. The historical founder context supports genuine conviction, but the BVI structure introduces opacity.
• Short public history: Softcare only listed in November 2025. There is no multi-year post-listing fundamental track record. Management guidance has not yet been tested against public-market delivery.

Sources

• HKEX News filings for Softcare Ltd (2698) — annual results announcement, March 2026; IPO prospectus, October 2025
• StockAnalysis.com — Softcare (HKG:2698) financials, balance sheet, cash flow, as of 3 Jun 2026
• Softcare HKEX DI filing — Yang Yanjuan disclosure of interests, June 2026
• Pyramids and Pagodas — Softcare Limited (2698.HK) company research
• MarketScreener, Yahoo Finance, Futunn — analyst consensus; Huachuang Securities initiating coverage
• Frost & Sullivan — African hygiene market size and CAGR projections (cited in IPO prospectus)
• Damodaran NYU Stern — equity risk premium, country risk premium, industry beta tables
• DCF and WACC computed via /Users/[USER]/.claude/skills/stock-valuation/scripts/ (dcf.py, wacc.py, reverse_dcf.py)